Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.31 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3871245 | 0.87 | TSHR (0.35) | TSHR | |
| SCHEMBL9622059 | 0.84 | TSHR (0.44) | TSHRLMNA | |
| SCHEMBL1930965 | 0.77 | TDP1 (0.38) | GRIK1SLC7A5 | |
| SCHEMBL27731214 | 0.75 | KDM4E (0.36) | GRIK1SLC7A5LMNA | |
| SCHEMBL28523 | 0.74 | FFAR3 (0.43) | TSHRSLC7A5LMNA | |
| SCHEMBL269877 | 0.74 | FFAR3 (0.43) | TSHRSLC7A5LMNA | |
| SCHEMBL1318841 | 0.73 | HDAC1 (0.42) | TSHRGRIK1 | |
| SCHEMBL8525838 | 0.73 | LMNA (0.46) | GRIK1LMNA | |
| SCHEMBL31463485 | 0.73 | ALDH1A1 (0.31) | — | |
| SCHEMBL4983762 | 0.73 | ALDH1A1 (0.41) | LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100081839-A1 | PROCESS FOR PREPARATION OF CRYSTALLINE CLOPIDOGREL HYDROGEN SULPHATE FORM I | IPCA LABORATORIES LTD. (IN) | 2010-04-01 | — | — | US | disclosed |
| EP-2114957-A2 | PROCESS FOR PREPARATION OF CRYSTALLINE CLOPIDOGREL HYDROGEN SULPHATE FORM I | IPCA Laboratories Limited (IN) | 2009-11-11 | — | — | EP | disclosed |
| US-20080188663-A1 | Process for the preparation of crystalline clopidogrel hydrogen sulphate Form I | IPCA LABORATORIES LIMITED (IN) | 2008-08-07 | — | — | US | disclosed |
| WO-2008093357-A2 | PROCESS FOR PREPARATION OF CRYSTALLINE CLOPIDOGREL HYDROGEN SULPHATE FORM I | IPCA LABORATORIES LIMITED (IN) | 2008-08-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100081839-A1 | PROCESS FOR PREPARATION OF CRYSTALLINE CLOPIDOGREL HYDROGEN SULPHATE FORM I | VKORC1, VKORC1L1, PTGER1 | TSHR 3025/4885GRIK1 1383/4885SLC7A5 4177/4885 |
| US-20080188663-A1 | Process for the preparation of crystalline clopidogrel hydrogen sulphate Form I | CYP2S1, CYP2F1, VKORC1L1 | TSHR 4697/4885GRIK1 1992/4885SLC7A5 4212/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.